Printer Friendly

THE IMMUNE RESPONSE CORPORATION RECEIVES U.S. PATENT ON HIV TECHNOLOGY

 CARLSBAD, Calif., Oct. 27 /PRNewswire/ -- The Immune Response Corporation (NASDAQ-NMS: IMNR) today announced the issuance of a United States patent relating to its HIV immunotherapeutic. The United States patent number 5,256,767 entitled "Retroviral Antigens," names Drs. Jonas Salk and Dennis J. Carlo as inventors and covers an HIV particle free of outer envelope proteins.
 The Immune Response Corporation, together with its joint venture partner, Rhone Poulenc-Rorer Inc., is using this patented technology to develop its HIV immunotherapeutic to treat HIV-infected individuals. The product is designed to boost the immune system and thereby allow the body's normal defense mechanism to control the virus.
 A multicenter Phase II/III clinical trial with the HIV immunotherapeutic has been completed. The joint venture is continuing to work with the FDA to review the results of this and prior studies to determine the appropriate next steps in this program in accordance with the FDA regulations on accelerated approvals for potential HIV therapies.
 "The allowance of broad composition of matter claims for our HIV immunotherapeutic enables us to establish a strong proprietary position," said Carlo, chief scientific officer of The Immune Response Corporation. FDA approval is required prior to marketing.
 The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection and autoimmune diseases, and through TargeTech Inc., gene therapy.
 -0- 10/27/93
 /CONTACT: Bronwyn LeMelle or Cindy Rollins, investor relations, of The Immune Response Corporation, 619-431-7080/
 (IMNR)


CO: The Immune Response Corporation ST: California IN: MTC SU: PDT

LM-JL -- SD006 -- 7634 10/27/93 21:54 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 27, 1993
Words:265
Previous Article:RHONE-POULENC RORER INCREASES DIVIDEND FOR NINTH CONSECUTIVE QUARTER; DIVIDEND UP 166 PERCENT IN 3 YEARS
Next Article:AIRLEASE ANNOUNCES INCREASED THIRD QUARTER RESULTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters